Everything below concerns MC4R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Different authors linked these groups either to lepidosauromorphs or to archosauromorphs, and ichthyopterygians were also argued to be diapsids that did not belong to the least inclusive clade containing lepidosauromorphs and archosauromorphs.
A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing. (NCI) The process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. (NLM) A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form. (ICH E6) Informed consent document
=== Chemistry === Dry soybeans contain 36% protein and 20% fat in form of soybean oil by weight. The remainder consists of 30% carbohydrates, 9% water and 5% ash. Soybeans comprise approximately 8% seed coat or hull, 90% cotyledons and 2% hypocotyl axis or germ.
Sources: en.wikipedia.org
=== Sample concentration and mobile phase flow rate === Dilution of sample or reducing the volume of sample injected may give a reduction of ion suppression by reducing the quantity of interfering species present, although the quantity of analyte of interest will also be reduced, making this an undesirable approach for trace analysis. Similar is the effect of reducing the mobile phase flow rate to the nanolitre-per-minute range since, in addition to resulting in improved desolvation, the smaller droplets formed are more tolerant to the presence of non-volatile species in the sample matrix.
=== Scientific analyses === Cultural considerations can sometimes interfere with the conservation of human remains, particularly when it comes to physical and chemical analyses, which play an important role in their care. Testing conducted on human remains, especially ancient ones, can include DNA testing, isotope analyses, and carbon-14 dating. The benefits of such testing is sometimes outweighed by the cultural or sacred importance of the remains as well as the risk of damaging them too greatly. According to the Deutscher Museumsbund, there are only three circumstances in which scientific research should be conducted on human remains:
=== Criminal justice and cannabis legalization === In 2014, Newsom was the only statewide politician to endorse California Proposition 47, legislation that recategorized certain nonviolent offenses from felonies to misdemeanors, including shoplifting, grand theft, and receiving stolen property valued at under $950. Voters passed the measure on November 4, 2014. In July 2015, Newsom released the Blue Ribbon Commission on Marijuana Policy's final report, which he had convened with the American Civil Liberties Union of California in 2013. The report's recommendations to regulate cannabis were intended to inform a legalization measure on the November 2016 ballot. Newsom supported the resulting measure, Proposition 64, which legalized cannabis use and cultivation for California state residents who are 21 or older. On February 24, 2017, in response to pro-enforcement statements by White House Press Secretary Sean Spicer, Newsom sent Attorney General Jeff Sessions and President Donald Trump a letter urging them not to increase federal enforcement against recreational cannabis firms opening in California. He wrote: "The government must not strip the legal and publicly supported industry of its business and hand it back to drug cartels and criminals ... Dealers don't card kids.
Sources: en.wikipedia.org
Draft scripts for Half-Life 2 indicate that this would have been shown in an introductory segment to the game carried out through a series of projector slides. One of the slides would have shown Breen at the foot of a tower wearing a headset linked directly to it, with arms held wide and speaking to the skies. Breen is alerted to the return of Gordon Freeman in Half-Life 2 when Gordon is temporarily teleported, by accident, to his office in the Citadel. Dr. Breen informs the Combine and immediately dispatches the forces at his disposal to capture Freeman and break the associated Resistance movement in City 17. During Gordon Freeman's raid on the Citadel, Freeman is temporarily in the custody of Breen, until Judith Mossman turns against the administrator. During this period, Breen makes a very notable statement while in the presence of Alyx Vance and her father, Eli (who are also in his custody). He claims that Gordon "has proven a fine pawn to those who control him." He also comments that Gordon's services are "open to the highest bidder," and says he would understand if Gordon doesn't want to discuss it in front of his friends. These remarks imply that Breen may be aware of the mysterious G-Man and his influence over Freeman. It was also mentioned in one of the "Breencasts" to the Sector Seventeen Overwatch in Nova Prospekt; "I have good reason to believe that in the intervening years, he was in a state that precluded further development of covert skills." When Judith Mossman frees Gordon Freeman and Alyx Vance in his office, Dr.
===== Methane ===== Methane produced by marine methanogens is typically more D-enriched than methane produced by methanogens grown in freshwater. δDs for thermogenic methane range from −275‰ to −100‰, and from −400‰ to −150‰ for microbial methane.
== Mutations == Mutations in genes encoding uniporters lead to dysfunctional transporter proteins being formed. This loss of function in uniporters causes disruption in cellular function which leads to various diseases and disorders.
The term "concentration camp" was used to describe camps operated by the British in South Africa during this conflict in the years 1900–02, and the term grew in prominence during this period. The camps had originally been set up by the British Army as "refugee camps" to provide refuge for civilian families who had been forced to abandon their homes for whatever reason related to the war. However, when Kitchener took over in late 1900, he introduced new tactics in an attempt to break the guerrilla campaign and the influx of civilians grew dramatically as a result. Disease and starvation killed thousands. Kitchener initiated plans to
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.